{"pmid":32405833,"title":"[Hypertension and RAAS inhibition in times of COVID-19 - current recommendations of the European Society of Hypertension.]","text":["[Hypertension and RAAS inhibition in times of COVID-19 - current recommendations of the European Society of Hypertension.]","MMW Fortschr Med","Limbourg, Florian P","32405833"],"journal":"MMW Fortschr Med","authors":["Limbourg, Florian P"],"date":"2020-05-15T11:00:00Z","year":2020,"_id":"32405833","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1007/s15006-020-0483-y","keywords":["covid-19","hypertension","raas-inhibition"],"weight":0,"_version_":1666802845581574144,"score":9.490897,"similar":[{"pmid":32266708,"pmcid":"PMC7138256","title":"Renin-Angiotensin System Inhibition in Cardiovascular Patients at the Time of COVID19: Much Ado for Nothing? A Statement of Activity from the Directors of the Board and the Scientific Directors of the Italian Society of Hypertension.","text":["Renin-Angiotensin System Inhibition in Cardiovascular Patients at the Time of COVID19: Much Ado for Nothing? A Statement of Activity from the Directors of the Board and the Scientific Directors of the Italian Society of Hypertension.","Cardiovascular diseases, in particular hypertension, as well as the cardiovascular treatment with Renin-Angiotensin System inhibitors such as Angiotensin Converting Enzyme (ACE) inhibitors and Angiotensin Receptor Blockers (ARBs), are claimed once again as mechanisms of Severe Acute Respiratory Syndrome (SARS) during the COVID-19 outbreak due to Cov-2 epidemics. In vitro studies are available to support the eventual role of ACE inhibitors and ARBs in both the promotion and antagonism of the disease. The available literature, indeed, presents contrasting results, all concentrated in experimental models. Evidence in humans is lacking that those mechanisms are actually occurring in the present COVID-19 outbreak. Here we present the reasoned statement of the Italian Society of Hypertension to maintain ongoing antihypertensive treatments. Furthermore, the Italian Society of Hypertension presents its own initiative to investigate the issue using an online questionnaire to collect relevant data in human disease.","High Blood Press Cardiovasc Prev","Iaccarino, Guido","Borghi, Claudio","Cicero, Arrigo F G","Ferri, Claudio","Minuz, Pietro","Muiesan, Maria Lorenza","Mulatero, Paolo","Mule, Giuseppe","Pucci, Giacomo","Salvetti, Massimo","Savoia, Carmine","Sechi, Leonardo Alberto","Volpe, Massimo","Grassi, Guido","32266708"],"abstract":["Cardiovascular diseases, in particular hypertension, as well as the cardiovascular treatment with Renin-Angiotensin System inhibitors such as Angiotensin Converting Enzyme (ACE) inhibitors and Angiotensin Receptor Blockers (ARBs), are claimed once again as mechanisms of Severe Acute Respiratory Syndrome (SARS) during the COVID-19 outbreak due to Cov-2 epidemics. In vitro studies are available to support the eventual role of ACE inhibitors and ARBs in both the promotion and antagonism of the disease. The available literature, indeed, presents contrasting results, all concentrated in experimental models. Evidence in humans is lacking that those mechanisms are actually occurring in the present COVID-19 outbreak. Here we present the reasoned statement of the Italian Society of Hypertension to maintain ongoing antihypertensive treatments. Furthermore, the Italian Society of Hypertension presents its own initiative to investigate the issue using an online questionnaire to collect relevant data in human disease."],"journal":"High Blood Press Cardiovasc Prev","authors":["Iaccarino, Guido","Borghi, Claudio","Cicero, Arrigo F G","Ferri, Claudio","Minuz, Pietro","Muiesan, Maria Lorenza","Mulatero, Paolo","Mule, Giuseppe","Pucci, Giacomo","Salvetti, Massimo","Savoia, Carmine","Sechi, Leonardo Alberto","Volpe, Massimo","Grassi, Guido"],"date":"2020-04-09T11:00:00Z","year":2020,"_id":"32266708","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.1007/s40292-020-00380-3","keywords":["covid-19","cardiovascular diseases","hypertension","infection","outcomes"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138491961999361,"score":74.44853},{"pmid":32359088,"title":"RAAS blockers in hypertension posing a higher risk towards the COVID-19.","text":["RAAS blockers in hypertension posing a higher risk towards the COVID-19.","Dermatol Ther","Singh, Yogendra","Gupta, Gaurav","Satija, Saurabh","Negi, Poonam","Chellappan, Dinesh Kumar","Dua, Kamal","32359088"],"journal":"Dermatol Ther","authors":["Singh, Yogendra","Gupta, Gaurav","Satija, Saurabh","Negi, Poonam","Chellappan, Dinesh Kumar","Dua, Kamal"],"date":"2020-05-03T11:00:00Z","year":2020,"_id":"32359088","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1111/dth.13501","topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138495339462658,"score":68.77514},{"pmid":32405229,"pmcid":"PMC7217779","title":"COVID-19, hypertension and cardiovascular diseases: Should we change the therapy?","text":["COVID-19, hypertension and cardiovascular diseases: Should we change the therapy?","The coronavirus disease (COVID-19) has spread all around the world in a very short period of time. Recent data are showing significant prevalence of arterial hypertension and cardiovascular diseases (CVD) among patients with COVID-19, which raised many questions about higher susceptibility of patients with these comorbidities to the novel coronavirus, as well as the role of hypertension and CVD in progression and the prognosis of COVID-19 patients. There is a very limited amount of data, usually obtained from a small population, regarding the effect of the underlying disease on the outcome in patients with COVID-19. The evaluation of the treatment of these comorbidities at baseline and during COVID-19 is scarce and the results are conflicting. Hypertension and CVD, after the adjustment for other clinical and demographic parameters, primarily age, did not remain independent predictors of the lethal outcome in COVID-19 patients. Some investigations speculated about the association between the renin-angiotensin-aldosterone system (RAAS) and susceptibility to COVID-19, as well as the relationship between RAAS inhibitors and the adverse outcome in these patients. Withdrawing or switching RAAS inhibitors would have uncertain benefits, but it would definitely have many disadvantages such as uncontrolled hypertension, cardiac function deterioration and renal function impairment, which could potentially induce more complications in patients with COVID-19 than the infection of coronavirus itself. The aim of this review article was to summarize the prevalence of hypertension and CVD in patients with COVID-19, their influence on the outcome and the effect of treatment of hypertension and CVD in COVID-19 patients.","Pharmacol Res","Tadic, Marijana","Cuspidi, Cesare","Mancia, Giuseppe","Dell'Oro, Raffaella","Grassi, Guido","32405229"],"abstract":["The coronavirus disease (COVID-19) has spread all around the world in a very short period of time. Recent data are showing significant prevalence of arterial hypertension and cardiovascular diseases (CVD) among patients with COVID-19, which raised many questions about higher susceptibility of patients with these comorbidities to the novel coronavirus, as well as the role of hypertension and CVD in progression and the prognosis of COVID-19 patients. There is a very limited amount of data, usually obtained from a small population, regarding the effect of the underlying disease on the outcome in patients with COVID-19. The evaluation of the treatment of these comorbidities at baseline and during COVID-19 is scarce and the results are conflicting. Hypertension and CVD, after the adjustment for other clinical and demographic parameters, primarily age, did not remain independent predictors of the lethal outcome in COVID-19 patients. Some investigations speculated about the association between the renin-angiotensin-aldosterone system (RAAS) and susceptibility to COVID-19, as well as the relationship between RAAS inhibitors and the adverse outcome in these patients. Withdrawing or switching RAAS inhibitors would have uncertain benefits, but it would definitely have many disadvantages such as uncontrolled hypertension, cardiac function deterioration and renal function impairment, which could potentially induce more complications in patients with COVID-19 than the infection of coronavirus itself. The aim of this review article was to summarize the prevalence of hypertension and CVD in patients with COVID-19, their influence on the outcome and the effect of treatment of hypertension and CVD in COVID-19 patients."],"journal":"Pharmacol Res","authors":["Tadic, Marijana","Cuspidi, Cesare","Mancia, Giuseppe","Dell'Oro, Raffaella","Grassi, Guido"],"date":"2020-05-15T11:00:00Z","year":2020,"_id":"32405229","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.phrs.2020.104906","keywords":["covid-19","cardiovascular disease","hypertension","outcome"],"e_drugs":["Aldosterone"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666950579778224130,"score":65.8837},{"pmid":32461198,"title":"COVID-19, hypertension and cardiovascular diseases: Should we change the therapy?","text":["COVID-19, hypertension and cardiovascular diseases: Should we change the therapy?","The coronavirus disease (COVID-19) has spread all around the world in a very short period of time. Recent data are showing significant prevalence of arterial hypertension and cardiovascular diseases (CVD) among patients with COVID-19, which raised many questions about higher susceptibility of patients with these comorbidities to the novel coronavirus, as well as the role of hypertension and CVD in progression and the prognosis of COVID-19 patients. There is a very limited amount of data, usually obtained from a small population, regarding the effect of the underlying disease on the outcome in patients with COVID-19. The evaluation of the treatment of these comorbidities at baseline and during COVID-19 is scarce and the results are conflicting. Hypertension and CVD, after the adjustment for other clinical and demographic parameters, primarily age, did not remain independent predictors of the lethal outcome in COVID-19 patients. Some investigations speculated about the association between the renin-angiotensin-aldosterone system (RAAS) and susceptibility to COVID-19, as well as the relationship between RAAS inhibitors and the adverse outcome in these patients. Withdrawing or switching RAAS inhibitors would have uncertain benefits, but it would definitely have many disadvantages such as uncontrolled hypertension, cardiac function deterioration and renal function impairment, which could potentially induce more complications in patients with COVID-19 than the infection of coronavirus itself. The aim of this review article was to summarize the prevalence of hypertension and CVD in patients with COVID-19, their influence on the outcome and the effect of treatment of hypertension and CVD in COVID-19 patients.","Pharmacol Res","Tadic, Marijana","Cuspidi, Cesare","Mancia, Giuseppe","Dell'Oro, Raffaella","Grassi, Guido","32461198"],"abstract":["The coronavirus disease (COVID-19) has spread all around the world in a very short period of time. Recent data are showing significant prevalence of arterial hypertension and cardiovascular diseases (CVD) among patients with COVID-19, which raised many questions about higher susceptibility of patients with these comorbidities to the novel coronavirus, as well as the role of hypertension and CVD in progression and the prognosis of COVID-19 patients. There is a very limited amount of data, usually obtained from a small population, regarding the effect of the underlying disease on the outcome in patients with COVID-19. The evaluation of the treatment of these comorbidities at baseline and during COVID-19 is scarce and the results are conflicting. Hypertension and CVD, after the adjustment for other clinical and demographic parameters, primarily age, did not remain independent predictors of the lethal outcome in COVID-19 patients. Some investigations speculated about the association between the renin-angiotensin-aldosterone system (RAAS) and susceptibility to COVID-19, as well as the relationship between RAAS inhibitors and the adverse outcome in these patients. Withdrawing or switching RAAS inhibitors would have uncertain benefits, but it would definitely have many disadvantages such as uncontrolled hypertension, cardiac function deterioration and renal function impairment, which could potentially induce more complications in patients with COVID-19 than the infection of coronavirus itself. The aim of this review article was to summarize the prevalence of hypertension and CVD in patients with COVID-19, their influence on the outcome and the effect of treatment of hypertension and CVD in COVID-19 patients."],"journal":"Pharmacol Res","authors":["Tadic, Marijana","Cuspidi, Cesare","Mancia, Giuseppe","Dell'Oro, Raffaella","Grassi, Guido"],"date":"2020-05-29T11:00:00Z","year":2020,"_id":"32461198","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1016/j.phrs.2020.104906","keywords":["covid-19","cardiovascular disease","hypertension","outcome"],"e_drugs":["Aldosterone"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668079521226555392,"score":65.8837},{"pmid":32479159,"title":"Related molecular mechanisms of COVID-19, hypertension, and diabetes.","text":["Related molecular mechanisms of COVID-19, hypertension, and diabetes.","Am J Physiol Endocrinol Metab","Akkus, Erman","Sahin, Mustafa","32479159"],"journal":"Am J Physiol Endocrinol Metab","authors":["Akkus, Erman","Sahin, Mustafa"],"date":"2020-06-02T11:00:00Z","year":2020,"_id":"32479159","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1152/ajpendo.00164.2020","keywords":["covid-19","diabetes","hypertension"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668437834921410560,"score":65.8837}]}